Caixin Global – Latest China News & Headlines

Home >

Beijing’s New Airport Invites Fierce Competition for Seoul and Paris Routes
China Welcomes International Institutions to Take Part in Belt and Road
Fosun Chairman Tells Jack Ma He’s Been ‘Thinking About Succession’
Foxconn to Manufacture Wearables in Chengdu
Baidu and ByteDance Launch Tit-for-Tat Lawsuit War
Services Giant Meituan Unveils Multi-Company Ride-Hailing Fleet — But Leaves Didi Out
Star Student Suspected of Killing Mother and Hiding Body for Months Finally Arrested
Leading Chinese Pig Provider Expands Business in Vietnam
Lawsuit Filer Says CEO Offered Her a Job at E-Commerce Giant Before Alleged Rape
Alibaba, Pinduoduo Wash Up on U.S. Piracy List
Payment Firm Lakala Cheers Investors With Surge in Shenzhen Debut
Chinese Sports Info Platform Prepares to Go Public, Again
Biotech Firm Viva to Raise Up to HK$1.5 Billion in Hong Kong IPO
At Least Three Electric Vehicles Have Spontaneously Exploded in China This Week
Fallen Tech Star LeEco's Listed Arm Braces for Trading Suspension
Central Bank Dismisses Rumors, Says It Will Not Tighten or Loosen Monetary Policy
Yet Another Chinese Coffee Chain Joins the Fundraising Frenzy
Former EV Head Is Being Detained — But No One Knows Where or by Whom
China's Bytedance Gets Reprieve as Indian Court Lifts Ban on TikTok App
Pork Company That Once Offered to Pay Debt With Ham Gets Stock-Market Warning
Huawei Opens Cloud and AI Innovation Lab
Guangdong Public Hospital Probed in Deaths of Newborns
China Welcomes International Institutions to Take Part in Belt and Road

By Bloomberg / Dec 06, 2018 04:18 PM / Finance

Photo: Bloomberg

Photo: Bloomberg

Chinese drug stocks headed for their worst drop in almost a decade amid concern the government is driving down prices for their products via a centralized procurement program.

The MSCI China Health Care Index plunged 8.1 percent at 2:34 p.m. in Hong Kong, with Sino Biopharmaceutical Ltd. sliding 14 percent. Much of the declines came after the midday break.

Prices on drugs that made into a government procurement list were cut substantially, the Shanghai Securities News reported, citing preliminary tender results. The price for one hepatitis B drug was cut by 90 percent and the price of another made by Jiangsu Hengrui Medicine Co. was reduced by 60 percent, according to the report.

The selloff is caused by speculation that a company had to lower their price by up to 90 percent to win a government bid, Kelvin Chen, a Bocom International analyst, said by phone. That triggered concern that companies involved in the bulk purchase scheme will have to massively cut prices to win orders.

Subscribe to Caixin Global now for 25% off.

Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.